| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $4.1M | -2.5% |
| SG&A Expense | $9.4M | +38.5% |
| Operating Income | -$13.5M | -22.8% |
| Net Income | -$13.2M | -24.3% |
| EPS (Basic) | -$6.64 | +23.9% |
| EPS (Diluted) | -$6.64 | +23.9% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $4.0M | -59.9% |
| Current Assets | $4.3M | -57.3% |
| Total Assets | $4.3M | -57.3% |
| Current Liabilities | $1.6M | -40.8% |
| Total Liabilities | $1.6M | -40.8% |
| Stockholders' Equity | $2.7M | -63.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$12.6M | -71.3% |
| Capital Expenditures | $5K | -21.9% |
| Investing Cash Flow | -$5K | +21.9% |
| Financing Cash Flow | $6.6M | -26.5% |
| Free Cash Flow | -$12.6M | -71.2% |